(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 34.93% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Nuvation Bio's revenue in 2026 is $169,900,000.On average, 14 Wall Street analysts forecast NUVB's revenue for 2026 to be $71,302,594,925, with the lowest NUVB revenue forecast at $60,631,959,874, and the highest NUVB revenue forecast at $81,390,365,409. On average, 14 Wall Street analysts forecast NUVB's revenue for 2027 to be $101,151,580,963, with the lowest NUVB revenue forecast at $77,215,510,169, and the highest NUVB revenue forecast at $127,791,300,650.
In 2028, NUVB is forecast to generate $150,161,361,825 in revenue, with the lowest revenue forecast at $106,527,277,660 and the highest revenue forecast at $222,682,354,369.